# ALIVUS — Alivus Life Sciences Limited

> Alivus Life Sciences Limited (ALIVUS) on the NSE: 1,250 sessions of split-adjusted history from 2021.

Canonical: https://patternsradar.com/s/ALIVUS

## Latest session

- Close: 1,350.9 INR (-1.39% on the day), 2026-08-21
- Delivery: 45.08% of volume taken to demat (20-day average 49.72%)
- Volume: 69.4K shares, turnover ₹9.4Cr
- Relative volume: 0.4× of its own 20-day average

## Technicals

- RSI(14): 62.86
- ATR(14): 46.88
- SMA 50: 1,190.68, SMA 200: 1,015.09
- 52-week range: 819 – 1,418 (-4.73% from the high)

## Performance

- 1 week -2.58%, 1 month 22.5%, 3 months 30.02%
- 6 months 49.88%, 1 year 40.95%

## Fundamentals

- Market cap: 16,585.2 crore
- P/E (TTM): 27.5 — NULL when trailing earnings are negative or unfiled, never a misleading number
- EPS (TTM): 49.12 INR, split-adjusted to match the price series
- Revenue growth: 6.41% YoY, -7.07% QoQ
- Profit growth: 31.71% YoY, -1.59% QoQ

Compound annual growth, trailing-twelve-month against the same measure N years earlier:

| Window | Revenue | Profit |
| --- | --- | --- |
| 2y | 6.28% | 16.16% |
| 3y | 4.81% | 6.9% |
| 4y | 5.54% | 9.04% |

## Quarterly results

Last 8 filed quarters, standalone basis, in rupees crore as filed.

| Quarter | Revenue | Total expenses | Profit before tax | Net profit | EPS | Net margin |
| --- | --- | --- | --- | --- | --- | --- |
| 2024-09-30 | 506.9 | 388 | 127.5 | 95.3 | 7.78 | 18.8% |
| 2024-12-31 | 641.8 | 467.2 | 185.1 | 137 | 11.18 | 21.34% |
| 2025-03-31 | 649.5 | 468.3 | 191.3 | 141.9 | 11.57 | 21.84% |
| 2025-06-30 | 601.8 | 447.9 | 163 | 121.5 | 9.91 | 20.19% |
| 2025-09-30 | 588 | 428.6 | 174.1 | 130 | 10.6 | 22.11% |
| 2025-12-31 | 672.9 | 462.8 | 198.4 | 150.3 | 12.25 | 22.33% |
| 2026-03-31 | 689.1 | 496.1 | 215.8 | 162.7 | 13.23 | 23.6% |
| 2026-06-30 | 640.4 | 450.6 | 212.2 | 160.1 | 13.04 | 25% |

A quarterly filing with NSE carries a profit and loss only. There is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure in this dataset. EPS is restated onto the split-adjusted basis the price series uses; every rupee figure is exactly as filed.

## Shareholding

As filed for 2026-06-30:

- Promoter: 74.87%
- Public: 25.13%

Institutional and pledge percentages come from a filing stage whose backfill has reached about 1% of instruments, so they are absent here rather than zero.

## Recent filings

- 2026-07-30: results for 2026-06-30 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_180844_30072026191858_iXBRL_WEB.html
- 2026-07-13: shareholding for 2026-06-30 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1691569_13072026052027_WEB.xml
- 2026-05-14: results for 2026-03-31 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_157731_14052026205118_iXBRL_WEB.html
- 2026-04-14: shareholding for 2026-03-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1650841_14042026061605_WEB.xml
- 2026-01-22: results for 2025-12-31 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_136721_22012026160613_iXBRL_WEB.html
- 2026-01-19: shareholding for 2025-12-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1604782_19012026070613_WEB.xml
- 2025-11-06: results for 2025-09-30 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_124921_06112025191327_iXBRL_WEB.html
- 2025-10-10: shareholding for 2025-09-30 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1544512_10102025050008_WEB.xml

Dated by the day the company broadcast the filing. 48 events are indexed for this instrument.

## About the instrument

- Listed: 2021-08-06 — latest session 2026-08-21 (1,250 sessions)
- ISIN: INE03Q201024
- Series: EQ
- Liquidity rank: #726 by 20-day average turnover — not index membership

Delivery figures come from NSE's daily reports and are unavailable for older sessions. Prices are end-of-day, split- and bonus-adjusted, from the eod2 dataset.

Charts and the full bar history are on the rendered page: https://patternsradar.com/s/ALIVUS.